Processa Pharmaceuticals Will Evaluate HT-100 as Treatment for IPF, Other Fibrotic Diseases
- Volcani International Partnerships
- Sep 6, 2019
- 1 min read
HT 100, an anti-inflammatory compound discovered by Mark Pines at the Volcani Institute, will be further developed by Processa Pharmaceuticals.
Comments